Literature DB >> 26095632

Targeted Anti-Anticoagulants.

Kenneth A Bauer1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26095632     DOI： 10.1056/NEJMe1506600

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  [Perioperative management of patients on NOACs].

Authors:  C Kelm; K Engels
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-12       Impact factor: 0.840

2.  The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.

Authors:  Pavel Goriacko; Vicken Yaghdjian; Issam Koleilat; Mark Sinnett; Harshal Shukla
Journal:  P T       Date:  2017-11

3.  Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.

Authors:  Sophie Testa; Walter Ageno; Emilia Antonucci; Rossella Morandini; Jan Beyer-Westendorf; Maurizio Paciaroni; Marc Righini; Piera Sivera; Peter Verhamme; Vittorio Pengo; Daniela Poli; Gualtiero Palareti
Journal:  Intern Emerg Med       Date:  2018-05-22       Impact factor: 3.397

4.  Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Walter Ageno; Marcello Ciaccio; Cristina Legnani; Giuseppe Lippi; Cesare Manotti; Rossella Marcucci; Marco Moia; Benedetto Morelli; Daniela Poli; Agostino Steffan; Sophie Testa
Journal:  Blood Transfus       Date:  2017-09-13       Impact factor: 3.443

5.  Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.

Authors:  Toshiaki Iba; Mari Emmi; Makoto Hiki; Masataka Nagayama; Koichiro Aihara; Yoko Tabe; Maiko Yuri; Akimichi Ohsaka
Journal:  Int J Hematol       Date:  2016-03-16       Impact factor: 2.490

Review 6.  Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.

Authors:  Mark Walsh; Stephanie Fritz; Daniel Hake; Michael Son; Sarah Greve; Manar Jbara; Swetha Chitta; Braxton Fritz; Adam Miller; Mary K Bader; Jonathon McCollester; Sophia Binz; Alyson Liew-Spilger; Scott Thomas; Anton Crepinsek; Faisal Shariff; Victoria Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

7.  International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study.

Authors:  Fanny Ofek; Dana Barchel; Nofar Perets; Tomer Ziv-Baran; Ahmad Mahajna; Talia Filipovich-Rimon; Osnat Garach-Jehoshua; Maya Berlin; Matitiahu Berkovitch
Journal:  Front Pharmacol       Date:  2019-10-08       Impact factor: 5.810

Review 8.  Novel antidotes for target specific oral anticoagulants.

Authors:  Arundhati Das; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2015-09-15

Review 9.  New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).

Authors:  Rick H van Gorp; Leon J Schurgers
Journal:  Nutrients       Date:  2015-11-17       Impact factor: 5.717

10.  "Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?

Authors:  H-G Eichler; B Bloechl-Daum; P Bauer; F Bretz; J Brown; L V Hampson; P Honig; M Krams; H Leufkens; R Lim; M M Lumpkin; M J Murphy; F Pignatti; M Posch; S Schneeweiss; M Trusheim; F Koenig
Journal:  Clin Pharmacol Ther       Date:  2016-10-19       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.